Blood Pharming of Red Cells.

Background: The transfusion of blood is an indispensable and irreplaceable component of contemporary medicine. Nevertheless, particularly in patients with very rare blood groups, the lack of blood products still represents a significant health problem on a global scale. In order to address this shortage, strategies for producing artificial blood substitutes have been pursued for a period of time exceeding sixty years. Summary: This overview synthesises the latest advancements in the field of erythropoiesis, encompassing the expansion strategies for erythrocyte cells, the diverse sources of ex vivo expanded erythrocytes, the impediments to clinical implementation, the prospective applications, and alternative blood products. Conclusions: Ex vivo generation of red blood cells has advanced from proof-of-concept to early clinical testing, yet scalable, cost-effective manufacturing remains unresolved. Continued optimisation of cell sources, immortalised progenitor lines, and bioreactor technologies, alongside deeper mechanistic insights into terminal erythropoiesis and enucleation, will be key. Integrating these advances within rigorous regulatory frameworks could ultimately enable standardised, universally compatible RBC products.